23 July 2026
23 July 2026
AFTX-201 is an investigational gene therapy delivered through a single intravenous infusion.
Under the agreement, bioAffinity’s sputum analysis will be combined with Pictor’s proteomic platform to analyse inflammation.
The SpO₂ clip sensor features internal optical enhancements intended to improve signal quality and measurement accuracy.
In total, around 306 patients are expected to be enrolled in the trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
